MA37809A1 - Administration de médicament biodégradable pour compositions hydrophobes - Google Patents

Administration de médicament biodégradable pour compositions hydrophobes

Info

Publication number
MA37809A1
MA37809A1 MA37809A MA37809A MA37809A1 MA 37809 A1 MA37809 A1 MA 37809A1 MA 37809 A MA37809 A MA 37809A MA 37809 A MA37809 A MA 37809A MA 37809 A1 MA37809 A1 MA 37809A1
Authority
MA
Morocco
Prior art keywords
drug delivery
biodegradable drug
hydrophobic compositions
polyester
polyethylene glycol
Prior art date
Application number
MA37809A
Other languages
English (en)
Other versions
MA37809B1 (fr
Inventor
Georges Gaudriault
Christophe Roberge
Original Assignee
Medincell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37809(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medincell filed Critical Medincell
Publication of MA37809A1 publication Critical patent/MA37809A1/fr
Publication of MA37809B1 publication Critical patent/MA37809B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pour l'administration de médicament biodégradable comprenant un copolymère tribloc contenant un polyester et un polyéthylèneglycol et un copolymère dibloc contenant un polyester et un polyéthylèneglycol à coiffe terminale, ainsi qu'au moins une substance pharmaceutiquement active ou substance active hydrophobe telle que l'acétate de médroxyprogestérone, le lévonorgestrel, la cyclosporine, la progestérone ou la bupivacaïne.
MA37809A 2012-06-27 2013-06-27 Administration de médicament biodégradable pour compositions hydrophobes MA37809B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27
PCT/IB2013/001547 WO2014001904A1 (fr) 2012-06-27 2013-06-27 Administration de médicament biodégradable pour compositions hydrophobes

Publications (2)

Publication Number Publication Date
MA37809A1 true MA37809A1 (fr) 2017-07-31
MA37809B1 MA37809B1 (fr) 2018-12-31

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37809A MA37809B1 (fr) 2012-06-27 2013-06-27 Administration de médicament biodégradable pour compositions hydrophobes

Country Status (24)

Country Link
US (5) US20150150987A1 (fr)
EP (1) EP2866837B1 (fr)
JP (1) JP6134788B2 (fr)
KR (1) KR102189442B1 (fr)
CN (1) CN104582733B (fr)
AU (1) AU2013282891B2 (fr)
BR (1) BR112014031773B1 (fr)
CA (1) CA2877083C (fr)
CL (1) CL2014003531A1 (fr)
CO (1) CO7160098A2 (fr)
CR (1) CR20140581A (fr)
CU (1) CU24287B1 (fr)
EA (1) EA031522B1 (fr)
ES (1) ES2938586T3 (fr)
HK (1) HK1208374A1 (fr)
IL (1) IL236472B (fr)
IN (1) IN2014DN11063A (fr)
MA (1) MA37809B1 (fr)
MX (1) MX353280B (fr)
SG (1) SG11201408658PA (fr)
TN (1) TN2014000520A1 (fr)
UA (1) UA113549C2 (fr)
WO (2) WO2014001904A1 (fr)
ZA (1) ZA201409291B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015110915A2 (fr) * 2014-01-27 2015-07-30 Medincell Analogues rétro-inverso de spadine à effets antidépresseurs accrus
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
WO2016054197A1 (fr) * 2014-09-30 2016-04-07 University Of Tennessee Research Foundation Forme de gélification in situ pour l'administration de médicaments à action prolongée
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2016355236C1 (en) * 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2018081138A1 (fr) * 2016-10-24 2018-05-03 Yale University Implants contraceptifs biodégradables
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
WO2019016234A1 (fr) * 2017-07-17 2019-01-24 Medincell Composition pharmaceutique
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
CA3110250A1 (fr) * 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Compositions de cyclosporine et methodes d'utilisation
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
WO2021048817A1 (fr) 2019-09-13 2021-03-18 Medincell S.A. Formulations d'administration de médicaments
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
CN116847827A (zh) 2020-12-16 2023-10-03 美蒂森股份公司 用于预防性治疗SARS-CoV-2病毒（COVID-19）的方法和组合物
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
BR112023018652A2 (pt) 2021-03-17 2023-10-03 Medincell S A Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis
CN117222402A (zh) * 2021-04-30 2023-12-12 美蒂森股份公司 新制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US20040234472A1 (en) 2001-04-20 2004-11-25 Jackson John K. Micellar drug delivery systems for hydrophobic drugs
AU2002214466A1 (en) * 2000-11-09 2002-05-21 Astrazeneca Ab Oral pharmaceutical composition containing a block copolymer
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
DE602004007802T2 (de) * 2003-06-26 2008-04-17 Mediolanum Pharmaceuticals Ltd. Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
AU2006278328A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
EP2359860B1 (fr) * 2008-11-21 2014-08-06 Samyang Biopharmaceuticals Corporation Composition de micelles polymères pour le traitement de cellules cancéreuses résistantes
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
US9023897B2 (en) * 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions

Also Published As

Publication number Publication date
MX2014015902A (es) 2015-07-17
JP2015522001A (ja) 2015-08-03
BR112014031773B1 (pt) 2020-10-13
MA37809B1 (fr) 2018-12-31
EP2866837B1 (fr) 2022-12-14
CA2877083C (fr) 2020-10-06
SG11201408658PA (en) 2015-02-27
CL2014003531A1 (es) 2015-08-28
CU24287B1 (es) 2017-12-08
KR20150027265A (ko) 2015-03-11
US20190160171A1 (en) 2019-05-30
CN104582733B (zh) 2017-07-04
US20220354956A1 (en) 2022-11-10
US20150150987A1 (en) 2015-06-04
IN2014DN11063A (fr) 2015-09-25
IL236472B (en) 2020-02-27
HK1208374A1 (en) 2016-03-04
WO2014001905A1 (fr) 2014-01-03
BR112014031773A2 (pt) 2017-06-27
MX353280B (es) 2018-01-05
CU20140148A7 (es) 2015-03-30
IL236472A0 (en) 2015-02-26
ZA201409291B (en) 2017-05-31
CN104582733A (zh) 2015-04-29
TN2014000520A1 (en) 2016-03-30
AU2013282891A1 (en) 2015-01-22
AU2013282891B2 (en) 2018-04-12
AU2013282891A2 (en) 2015-02-05
EA201492172A1 (ru) 2015-09-30
CR20140581A (es) 2015-02-06
KR102189442B1 (ko) 2020-12-11
UA113549C2 (xx) 2017-02-10
CO7160098A2 (es) 2015-01-15
CA2877083A1 (fr) 2014-01-02
EP2866837A1 (fr) 2015-05-06
US20200085958A1 (en) 2020-03-19
WO2014001904A1 (fr) 2014-01-03
ES2938586T3 (es) 2023-04-12
US20210008216A1 (en) 2021-01-14
JP6134788B2 (ja) 2017-05-24
EA031522B1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
MA37809A1 (fr) Administration de médicament biodégradable pour compositions hydrophobes
MA34832B1 (fr) Compositions biodegradables d'administration de medicaments
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
WO2008008364A3 (fr) Compositions liquides de phényléphrine à stabilité améliorée
MX349725B (es) Forma de dosificacion farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o aversivo opioide, oxido de polialquileno y un polimero anionico.
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
EA201370006A1 (ru) Местная фармацевтическая композиция, содержащая флурбипрофен
MX2010005013A (es) Composiciones intranasales.
UA102120C2 (ru) Пероральная форма дозирования бендамустина
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
FR2984750B1 (fr) Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
EP4374861A3 (fr) Procédé de morcellement et/ou de ciblage de principes pharmaceutiquement actifs vers un tissu synovial
MA20150235A1 (fr) Utilisation de composition a base d'extraits de microalgues marines pour le traitement d'acne
WO2008027340A3 (fr) Formulations ophtalmiques locales
WO2012147101A3 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
MA46266B1 (fr) Formes cristallines
MA34130B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
TR201803451T4 (tr) Olmesartan formülasyonlari.
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
MX2021013488A (es) Formulaciones liquidas de dosis oral de metilnaltrexona.
WO2016014680A3 (fr) Compositions transmucosales orales comprenant des inhibiteurs d'aromatase pour lutter contre les faibles taux de testostérone chez les hommes